The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Pathologic complete response to cisplatin with dose-dense paclitaxel as neoadjuvant chemotherapy for locally advanced cervical cancer: Preliminary results of a multicenter phase II study with additional mutation analysis of adeno/adenosquamous carcinoma.
Maki Tanioka
No relevant relationships to disclose
Satoshi Yamaguchi
No relevant relationships to disclose
Shinya Sato
No relevant relationships to disclose
Shoji Nagao
No relevant relationships to disclose
Kazuhiro Takehara
No relevant relationships to disclose
Masato Nishimura
No relevant relationships to disclose
Tamotsu Sudo
No relevant relationships to disclose
Satoshi Morita
Honoraria - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
Hironobu Minami
Honoraria - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
Shunichi Negoro
No relevant relationships to disclose
Muneaki Shimada
No relevant relationships to disclose
Junzo Kigawa
No relevant relationships to disclose
Kiyoshi Fujiwara
No relevant relationships to disclose